This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).
Aged ≥18 years , regardless of gender.
Diagnosed with chronic kidney disease (CKD)
Urine albumin-creatinine ratio (UACR) of ≥300 mg/g and ≤5000 mg/g.
Serum potassium≥ lower limit of normal (LLN) and ≤4.8 mmol/L.
Had a documented diagnosis of autosomal dominant polycystic kidney disease or chronic kidney disease associated with infection or malignancy.
Had acute kidney injury or end-stage renal disease, received peritoneal dialysis, hemodialysis or kidney transplantation; or planned to undergo kidney transplantation or chronic renal replacement therapy during the study period.
Mean seated office systolic blood pressure (msSBP) ≥180 mmHg and/or mean seated office diastolic blood pressure (msDBP) ≥110 mmHg. History or diagnosis of malignant hypertension, hypertensive emergency, hypertensive crisis or hypertensive encephalopathy.
History or diagnostic evidence of other secondary hypertension.
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Lead sponsor